行情

ADXS

ADXS

Advaxis
NASDAQ

实时行情|Nasdaq Last Sale

0.5202
-0.0122
-2.29%
交易中 12:46 04/02 EDT
开盘
0.5400
昨收
0.5324
最高
0.5400
最低
0.5200
成交量
47.15万
成交额
--
52周最高
6.20
52周最低
0.2051
市值
3,133.99万
市盈率(TTM)
-0.1738
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ADXS价格均价为5.00,最高价位5.00,最低价为5.00。

EPS

ADXS 新闻

更多
  • Advaxis Is One Biotech That Should Be On Your Radar; Targeting Large NSCLC And Prostate Cancer Drug Markets
  • Seeking Alpha - Article · 03/16 09:41
  • Advaxis EPS beats by $0.04
  • seekingalpha · 03/13 18:34
  • Advaxis Reports First Quarter Ended January 31, 2020 Financial Results and Provides a Pipeline Update
  • GlobeNewswire · 03/13 14:00
  • Advaxis Q1 EPS $(0.15) Down From $2.76 YoY, Sales $3M Down From $19.689M YoY
  • Benzinga · 03/13 13:03

所属板块

生物技术和医学研究
+2.07%
制药与医学研究
+1.63%

热门股票

代码
价格
涨跌幅

ADXS 简况

Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.
展开

微牛提供Advaxis, Inc.(NASDAQ-ADXS)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ADXS股票新闻,以帮助您做出投资决策。